Welcome to our dedicated page for Corvus Pharmaceu news (Ticker: CRVS), a resource for investors and traders seeking the latest updates and insights on Corvus Pharmaceu stock.
Corvus Pharmaceuticals reports clinical, financing, governance, and financial updates for a clinical-stage biopharmaceutical company developing ITK inhibition as an immunotherapy approach for immune diseases and cancer. Its lead candidate, soquelitinib, is an investigational oral small molecule designed to selectively inhibit interleukin-2-inducible T cell kinase, a protein involved in T cell activation, signaling, differentiation, and function.
Recurring company news centers on soquelitinib clinical development in relapsed/refractory peripheral T cell lymphoma and atopic dermatitis, including immunologic and biomarker data presented at medical meetings. Updates also cover business results, public equity financing for research and development, board composition, and other clinical-stage pipeline disclosures.
Corvus Pharmaceuticals (Nasdaq: CRVS) recently presented interim data from its Phase 1/1b clinical trial of CPI-818 for T cell lymphoma at the Whistler Global Summit on Hematologic Malignancies. The data, revealed by Dr. John Reneau, indicates promising results with CPI-818 demonstrating monotherapy activity in relapsed patients. Key findings include one complete response lasting 24 months and an overall median progression-free survival (PFS) of 28.1 months for patients with an absolute lymphocyte count (ALC) above 900. Corvus aims to leverage this biomarker for patient enrollment in future trials.
Corvus Pharmaceuticals (CRVS) announced a business update and 2022 financial results on March 28, 2023. The company reported a cash balance of $42.3 million. The focus remains on CPI-818, an ITK inhibitor for T cell lymphoma, which has shown promising clinical data, with 20 patients enrolled in a Phase 1/1b trial. A predictive biomarker has been identified, indicating better tumor response rates with absolute lymphocyte counts above 900. The FDA has provided guidance for the next steps in clinical trials. Corvus also plans to pause CPI-818 development for atopic dermatitis to concentrate resources on cancer therapies.
Corvus Pharmaceuticals (Nasdaq: CRVS) will host a conference call and webcast on March 28, 2023, at 4:30 pm ET to present a business update and report its financial results for Q4 and full year 2022.
This session can be accessed through dial-in numbers provided or via a live webcast on the company's investor relations website. A replay will be available for 90 days post-call. Corvus is focused on developing innovative therapies, with its lead candidate, CPI-818, currently in a Phase 1/1b trial for T cell lymphomas. Other candidates include CPI-444 and CPI-006, which are in various stages of clinical trials.
Corvus Pharmaceuticals (Nasdaq: CRVS) announced new preclinical data for its drug CPI-818 during the ongoing Phase 1/1b clinical trial aimed at treating refractory T cell lymphoma. The data, to be presented at the AACR Annual Meeting from April 14-19, 2023, showcases CPI-818's anti-tumor activity in murine models, including complete tumor elimination in combination with anti-PD1 and anti-CTLA4 therapies. The findings suggest a broad potential for CPI-818 in solid tumors and indicate favorable immune responses, highlighting its role in enhancing tumor immunotherapy.
Corvus Pharmaceuticals (NASDAQ: CRVS) announced new data at the 30th Annual Conference on Retroviruses and Opportunistic Infections, showing the potential of CPI-818, an ITK inhibitor, to reduce reliance on chronic HIV therapy. The study involved two models, revealing a statistically significant reduction in the reversal of viral latency (P0.0001) when treated with CPI-818. This suggests that ITK inhibition may enable a 'block-and-lock' strategy to maintain viral suppression, potentially eliminating the need for lifelong antiretroviral therapy for people living with HIV. Further research will continue to develop novel HIV cure strategies.
Corvus Pharmaceuticals (CRVS) announced promising interim results from its Phase 1/1b trial of CPI-818, an ITK inhibitor targeting T cell lymphoma. The trial showed anti-tumor activity with 4 out of 11 evaluable patients achieving objective responses, including one complete response lasting 25 months. Corvus plans to initiate a Phase 2 trial in T cell lymphoma and a Phase 1 trial in atopic dermatitis in 2023. The data suggests CPI-818 effectively modulates T cell differentiation, indicating potential applications in autoimmune diseases as well.
Corvus Pharmaceuticals announced an investor conference call regarding CPI-818, an ITK inhibitor, on December 12, 2022, from 4:30 PM ET. The call will provide updates on data presented at the 64th ASH Annual Meeting and progress in the company's development programs. Highlights include results from the Phase 1/1b clinical trial targeting T-cell lymphomas and autoimmune diseases.
The ASH presentation will feature data on Th1 skewing in normal T cells, presented by Dr. Ryan Wilcox. Access details for the call and a 90-day webcast replay are available on the Corvus website.
On November 12, 2022, James T. Rosenbaum, MD, Senior VP of Research at Corvus Pharmaceuticals (Nasdaq: CRVS), received the Distinguished Service Award from the American College of Rheumatology (ACR), recognizing his contributions to rheumatology. Dr. Rosenbaum, who joined Corvus in July 2022, leads the development of CPI-818, an ITK inhibitor targeting immune disorders. Under his guidance, new clinical studies for CPI-818 are being prepared, with results from a Phase 1/1b trial to be shared at the upcoming ASH Annual Meeting from December 10-13, 2022.
Corvus Pharmaceuticals (CRVS) reported its Q3 2022 financial results and provided a business update, highlighting key milestones in drug development. The company focuses on CPI-818 for T cell lymphoma, with ongoing clinical trials showing promising patient responses and upcoming data to be presented at the ASH annual meeting. Additionally, a Phase 1b/2 trial for ciforadenant in renal cell cancer has commenced, and a Phase 1/1b trial for mupadolimab is approved in China. As of September 30, 2022, Corvus had cash reserves of $49.6 million, down from $69.5 million in 2021, with expected operational funding until early 2024.
Corvus Pharmaceuticals (NASDAQ: CRVS) will present new data from its Phase 1/1b trial of CPI-818, an ITK inhibitor, at the 64th American Society of Hematology Annual Meeting from December 10-13, 2022. The presentation will take place on December 12, 2022, at 6:00 PM ET, detailing CPI-818's effects on T-cell lymphoma and its potential in treating autoimmune diseases. Following the presentation, the company will host a conference call at 4:30 PM ET on the same day to discuss the findings. For further details, visit www.corvuspharma.com.